Page last updated: 2024-11-06

cymantrene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cymantrene, also known as bis(η5-cyclopentadienyl)manganese tricarbonyl, is an organometallic compound with the formula (η5-C5H5)2Mn(CO)3. It is a yellow, air-stable solid. Cymantrene is a versatile starting material for the synthesis of other organometallic compounds and has found applications in various fields, including catalysis, materials science, and medicine. Its unique structure and properties have attracted significant interest from researchers. For instance, the presence of the manganese atom with its carbonyl ligands allows for facile reactions with a variety of reagents. Its sandwich structure and the electron-withdrawing nature of the carbonyl groups influence its reactivity and stability. Cymantrene has been investigated as a catalyst for a variety of reactions, including the synthesis of organic compounds, the oxidation of organic molecules, and the polymerization of alkenes. Its ability to coordinate to various substrates makes it suitable for use in materials science, particularly in the development of novel polymers, sensors, and electronic devices. Cymantrene has also shown potential in medicinal chemistry, with studies exploring its activity against cancer cells and its use in the development of anti-inflammatory drugs. The study of cymantrene provides valuable insights into the chemistry of transition metals and their interaction with organic molecules. It serves as a model system for understanding the fundamental principles of organometallic chemistry, which has far-reaching implications for various chemical processes and technologies.'

Cross-References

ID SourceID
PubMed CID61551
MeSH IDM0130342

Synonyms (15)

Synonym
tricarbonyl(eta-cyclopentadienyl)manganese
cyklopentadientrikarbonylmanganium [czech]
hsdb 7191
manganese, cyclopentadienyltricarbonyl
manganese cyclopentadienyl tricarbonyl
manganese, tricarbonyl(eta5-2,4-cyclopentadien-1-yl)-
cymantrene
einecs 235-142-4
zcr03b0nfi ,
unii-zcr03b0nfi
tricarbonyl(.eta.-cyclopentadienyl)manganese
manganese cyclopentadienyl tricarbonyl [hsdb]
CENDTHIEZAWVHS-UHFFFAOYSA-N
Q1878572
DTXSID501014736

Research Excerpts

Overview

Cymantrene CpMn(CO)(3) is a robust organometallic group, stable in air and water and easy to functionalize.

ExcerptReferenceRelevance
"Cymantrene CpMn(CO)(3) is a robust organometallic group, which is stable in air and water and easy to functionalize."( Protease-activatable organometal-Peptide bioconjugates with enhanced cytotoxicity on cancer cells.
Gust, R; Hu, W; Neundorf, I; Onambele, LA; Ott, I; Prokop, A; Schatzschneider, U; Splith, K, 2010
)
1.08

Toxicity

ExcerptReferenceRelevance
" These results suggest that CMT does not require metabolic activation to produce toxic effects, and that prior exposure to CMT produces tolerance."( The acute toxicity of cyclopentadienyl manganese tricarbonyl in the rat.
Hanzlik, RP; Hogberg, K; Penney, DA; Traiger, GJ, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (14.29)18.7374
1990's5 (23.81)18.2507
2000's7 (33.33)29.6817
2010's4 (19.05)24.3611
2020's2 (9.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.33 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]